Narrative updates are currently in beta.

Back to narrative

European And Australian Medical Cannabis Markets Will Unlock Enduring Potential

ACB logo
ACB
AnalystConsensusTarget
Not Invested
Published 26 Apr 2025

Update shared on07 Aug 2025

Fair value Decreased 5.93%
Previous
AnalystConsensusTarget's Fair Value
CA$7.93
11.7% undervalued intrinsic discount
15 Aug
CA$7.00
Loading
1Y
-24.4%
7D
-2.5%

Despite substantial improvement in net profit margin and a sharply reduced future P/E ratio, the consensus analyst price target for Aurora Cannabis has decreased from CA$8.42 to CA$7.92.


What's in the News


  • Aurora Cannabis expects year-over-year net revenue growth in Q2 2026, primarily driven by an 8%–12% increase in its Global Medical Cannabis segment (Corporate Guidance – New/Confirmed, 2025-08-06).
  • The company expanded its compassionate pricing program in Canada, raising income eligibility from $40,000 to $60,000, and introduced new medical cannabis products targeting broader patient groups including seniors, veterans, and first responders (Product-Related Announcements, 2025-06-26).
  • Aurora launched IndiMed TEMPO 22 in Australia via MedReleaf, offering 22% THC potency in new Sativa and Indica cultivars, reinforcing its position as a leading prescribed medical cannabis brand in Australia (Product-Related Announcements, 2025-06-05).
  • The U.S. House approved an amendment allowing VA physicians to recommend medical cannabis in states where it is legal, potentially expanding addressable patient markets for companies like Aurora Cannabis (The Marijuana Herald, 2025-06-25).
  • Aurora continues its international expansion through product innovation and regulatory compliance, emphasizing growth in medical cannabis access and leadership in global markets (Product-Related Announcements, 2025-06-05 & 2025-06-26).

Valuation Changes


Summary of Valuation Changes for Aurora Cannabis

  • The Consensus Analyst Price Target has fallen from CA$8.42 to CA$7.92.
  • The Net Profit Margin for Aurora Cannabis has significantly risen from 7.72% to 21.12%.
  • The Future P/E for Aurora Cannabis has significantly fallen from 18.24x to 6.56x.

Disclaimer

AnalystConsensusTarget is a tool utilizing a Large Language Model (LLM) that ingests data on consensus price targets, forecasted revenue and earnings figures, as well as the transcripts of earnings calls to produce qualitative analysis. The narratives produced by AnalystConsensusTarget are general in nature and are based solely on analyst data and publicly-available material published by the respective companies. These scenarios are not indicative of the company's future performance and are exploratory in nature. Simply Wall St has no position in the company(s) mentioned. Simply Wall St may provide the securities issuer or related entities with website advertising services for a fee, on an arm's length basis. These relationships have no impact on the way we conduct our business, the content we host, or how our content is served to users. The price targets and estimates used are consensus data, and do not constitute a recommendation to buy or sell any stock, and they do not take account of your objectives, or your financial situation. Note that AnalystConsensusTarget's analysis may not factor in the latest price-sensitive company announcements or qualitative material.